Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-TKI”

285 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 285 results

Large-scale testing (Phase 3)Looking for participantsNCT06927986
What this trial is testing

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Who this might be right for
EGFR-mutated Locally Advanced or Metastatic NSCLC
CSPC Megalith Biopharmaceutical Co.,Ltd. 380
Large-scale testing (Phase 3)UnknownNCT02001896
What this trial is testing

Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation

Who this might be right for
Non-Small Cell Lung Cancer
Xinjiang Medical University 60
Large-scale testing (Phase 3)UnknownNCT06140186
What this trial is testing

Efficacy and Safety of Timolol for TKI Induced Paronychia

Who this might be right for
Paronychia
Queen Mary Hospital, Hong Kong 40
Not applicableNot Yet RecruitingNCT07338396
What this trial is testing

A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients

Who this might be right for
Non Small Cell Lung Cancer NSCLC
Guangzhou University of Traditional Chinese Medicine 3,000
Large-scale testing (Phase 3)Study completedNCT02864251
What this trial is testing

Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Who this might be right for
Non-Small-Cell Lung Carcinoma
Bristol-Myers Squibb 367
Testing effectiveness (Phase 2)Study completedNCT01588145
What this trial is testing

Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
Hanmi Pharmaceutical Company Limited 273
Testing effectiveness (Phase 2)Looking for participantsNCT06830694
What this trial is testing

Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

Who this might be right for
Small Cell Carcinoma of Lung
Se-Hoon Lee 50
Testing effectiveness (Phase 2)Ended earlyNCT05636267
What this trial is testing

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Who this might be right for
NSCLC
Akeso 59
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07343479
What this trial is testing

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Gene MutationsBrain Metastasis
Zhejiang Cancer Hospital 45
Large-scale testing (Phase 3)UnknownNCT02972333
What this trial is testing

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Who this might be right for
EGFR-TKI Resistant MutationNonsmall Cell Lung CancerAZD9291+1 more
Shandong Cancer Hospital and Institute 150
Large-scale testing (Phase 3)Not Yet RecruitingNCT07109531
What this trial is testing

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 286
Not applicableLooking for participantsNCT05598528
What this trial is testing

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

Who this might be right for
Lung Cancer, Non-small CellEGFR Gene MutationEGFR-TKI Resistant Mutation+2 more
Second Xiangya Hospital of Central South University 210
Early research (Phase 1)Study completedNCT06221475
What this trial is testing

Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants

Who this might be right for
Advanced Non-small Cell Lung CancerEGFR MutationHER2 Mutation+1 more
Bayer 8
Very early researchNot Yet RecruitingNCT07498595
What this trial is testing

TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC

Who this might be right for
EGFR-TKI-resistant Non-Small Cell Lung Cancer
Tianjin Medical University General Hospital 50
Testing effectiveness (Phase 2)UnknownNCT06334757
What this trial is testing

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Henan Cancer Hospital 46
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Testing effectiveness (Phase 2)UnknownNCT04405674
What this trial is testing

Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Chest Hospital 120
Not applicableStudy completedNCT03059641
What this trial is testing

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China

Who this might be right for
Lung NeoplasmsLung Cancer, Nonsmall CellAdenocarcinoma of Lung+1 more
Geneplus-Beijing Co. Ltd. 300
Not applicableWithdrawnNCT02368990
What this trial is testing

T790M Mutation Positive 2nd Line STandard of cAre Registry

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca
Early research (Phase 1)Ended earlyNCT02206763
What this trial is testing

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
EGFR Mutated EGFR TKI Naive Metastatic NSCLC
Sierra Oncology LLC - a GSK company 11
Load More Results